COLLEGE OF MEDICINE AND HEALTH
Medicine, Nursing and Allied Health Professions

Loading content
 Martin Eichmann

Martin Eichmann

Lecturer in Immunology

 RILD Building Level 4

 

University of Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road, Exeter, EX2 5DW, UK

Overview

Martin is a recent recruit to the Diabetes Center of Excellence, and joined the University of Exeter Medical School as a Lecturer in Immunology, in June 2020. Over the past decade he worked with Professor Mark Peakman, at King’s College London. There, Martin developed a particular interest for mechanisms of antigen processing and presentation, and the characterization of autoreactive T cells in the setting of autoimmune type 1 diabetes.

Qualifications

  • 2010-2014 - PhD in Immunology, King’s College London, U.K. “Genes and Phenotypes in type 1 diabetes”, awarded January 2015
  • 2009 - BSc(Hons) in Bioengineering, Munich University of Applied Sciences, Germany

Research

Research interests

Martin’s research focuses on the question as to why T cell-directed immunotherapy strategies in autoimmune type 1 diabetes are of limited efficacy. His work approaches this via two distinct research settings: 1) Elucidating mechanisms of antigen processing and presentation on pancreatic beta cells, and 2) Phenotypically characterize beta-cell-specific T cells. New research findings from this work could form the basis to adapt existing or initiate novel strategies for immunotherapy and to allow to better monitor disease progression in individuals at risk to develop type 1 diabetes.

Research projects

  • Novel Mechanisms for Generation of Islet Autoantigens
  • The Effects of Genetic Predisposition on T cells

Publications

Key publications | Publications by category | Publications by year

Publications by category


Journal articles

Kronenberg-Versteeg D, Eichmann M, Russell MA, de Ru A, Hehn B, Yusuf N, van Veelen PA, Richardson SJ, Morgan NG, Lemburg MK, et al (In Press). Molecular pathways for immune recognition of preproinsulin signal peptide in type 1 diabetes. Diabetes Full text.
Yeo L, Pujol-Autonell I, Baptista R, Eichmann M, Kronenberg-Versteeg D, Heck S, Dolton G, Sewell AK, Harkonen T, Mikk M-L, et al (2020). Circulating beta cell-specific CD8(+) T cells restricted by high-risk HLA class I molecules show antigen experience in children with and at risk of type 1 diabetes. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 199(3), 263-277. Author URL.
Eichmann M, Baptista R, Ellis RJ, Heck S, Peakman M, Beam CA (2020). Costimulation Blockade Disrupts CD4+ T Cell Memory Pathways and Uncouples Their Link to Decline in β-Cell Function in Type 1 Diabetes. J Immunol, 204(12), 3129-3138. Abstract.  Author URL.
Yeo L, Woodwyk A, Sood S, Lorenc A, Eichmann M, Pujol-Autonell I, Melchiotti R, Skowera A, Fidanis E, Dolton GM, et al (2018). Autoreactive T effector memory differentiation mirrors beta cell function in type 1 diabetes. JOURNAL OF CLINICAL INVESTIGATION, 128(8), 3460-3474. Author URL.
Ali MA, Liu Y-F, Arif S, Tatovic D, Shariff H, Gibson VB, Yusuf N, Baptista R, Eichmann M, Petrov N, et al (2017). Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. SCIENCE TRANSLATIONAL MEDICINE, 9(402). Author URL.
Harbige J, Eichmann M, Peakman M (2017). New insights into non-conventional epitopes as T cell targets: the missing link for breaking immune tolerance in autoimmune disease?. JOURNAL OF AUTOIMMUNITY, 84, 12-20. Author URL.
Gomez-Tourino I, Arif S, Eichmann M, Peakman M (2016). T cells in type 1 diabetes: Instructors, regulators and effectors: a comprehensive review. JOURNAL OF AUTOIMMUNITY, 66, 7-16. Author URL.
Knight RR, Dolton G, Kronenberg-Versteeg D, Eichmann M, Zhao M, Huang GC, Beck K, Cole DK, Sewell AK, Skowera A, et al (2015). A distinct immunogenic region of glutamic acid decarboxylase 65 is naturally processed and presented by human islet cells to cytotoxic CD8 T cells. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 179(1), 100-107. Author URL.
Collison JL, Carlin LM, Eichmann M, Geissmann F, Peakman M (2015). Heterogeneity in the Locomotory Behavior of Human Monocyte Subsets over Human Vascular Endothelium in Vitro. JOURNAL OF IMMUNOLOGY, 195(3), 1162-1170. Author URL.
Skowera A, Ladell K, McLaren JE, Dolton G, Matthews KK, Gostick E, Kronenberg-Versteeg D, Eichmann M, Knight RR, Heck S, et al (2015). beta-Cell-Specific CD8 T Cell Phenotype in Type 1 Diabetes Reflects Chronic Autoantigen Exposure. DIABETES, 64(3), 916-925. Author URL.
Eichmann M, de Ru A, van Veelen PA, Peakman M, Kronenberg-Versteeg D (2014). Identification and characterisation of peptide binding motifs of six autoimmune disease-associated human leukocyte antigen-class I molecules including HLA-B*39:06. TISSUE ANTIGENS, 84(4), 378-388. Author URL.
Knight RR, Kronenberg D, Zhao M, Huang GC, Eichmann M, Bulek A, Wooldridge L, Cole DK, Sewell AK, Peakman M, et al (2013). Human beta-Cell Killing by Autoreactive Preproinsulin-Specific CD8 T Cells is Predominantly Granule-Mediated with the Potency Dependent Upon T-Cell Receptor Avidity. DIABETES, 62(1), 205-213. Author URL.
Kronenberg D, Knight RR, Estorninho M, Ellis RJ, Kester MG, de Ru A, Eichmann M, Huang GC, Powrie J, Dayan CM, et al (2012). Circulating Preproinsulin Signal Peptide-Specific CD8 T Cells Restricted by the Susceptibility Molecule HLA-A24 Are Expanded at Onset of Type 1 Diabetes and Kill beta-Cells. DIABETES, 61(7), 1752-1759. Author URL.
Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Hoefler H, Hegewisch-Becker S, Folprecht G, et al (2011). Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC CANCER, 11 Author URL.

Chapters

Eichmann M, Peakman M (2013). The role of T lymphocytes in the pathogenesis of autoimmune type 1 diabetes: Implications for potential virus-mediated pathways. In  (Ed) Diabetes and Viruses, 271-286.  Abstract.

Publications by year


In Press

Kronenberg-Versteeg D, Eichmann M, Russell MA, de Ru A, Hehn B, Yusuf N, van Veelen PA, Richardson SJ, Morgan NG, Lemburg MK, et al (In Press). Molecular pathways for immune recognition of preproinsulin signal peptide in type 1 diabetes. Diabetes Full text.

2020

Yeo L, Pujol-Autonell I, Baptista R, Eichmann M, Kronenberg-Versteeg D, Heck S, Dolton G, Sewell AK, Harkonen T, Mikk M-L, et al (2020). Circulating beta cell-specific CD8(+) T cells restricted by high-risk HLA class I molecules show antigen experience in children with and at risk of type 1 diabetes. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 199(3), 263-277. Author URL.
Eichmann M, Baptista R, Ellis RJ, Heck S, Peakman M, Beam CA (2020). Costimulation Blockade Disrupts CD4+ T Cell Memory Pathways and Uncouples Their Link to Decline in β-Cell Function in Type 1 Diabetes. J Immunol, 204(12), 3129-3138. Abstract.  Author URL.

2018

Yeo L, Woodwyk A, Sood S, Lorenc A, Eichmann M, Pujol-Autonell I, Melchiotti R, Skowera A, Fidanis E, Dolton GM, et al (2018). Autoreactive T effector memory differentiation mirrors beta cell function in type 1 diabetes. JOURNAL OF CLINICAL INVESTIGATION, 128(8), 3460-3474. Author URL.

2017

Ali MA, Liu Y-F, Arif S, Tatovic D, Shariff H, Gibson VB, Yusuf N, Baptista R, Eichmann M, Petrov N, et al (2017). Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. SCIENCE TRANSLATIONAL MEDICINE, 9(402). Author URL.
Harbige J, Eichmann M, Peakman M (2017). New insights into non-conventional epitopes as T cell targets: the missing link for breaking immune tolerance in autoimmune disease?. JOURNAL OF AUTOIMMUNITY, 84, 12-20. Author URL.

2016

Gomez-Tourino I, Arif S, Eichmann M, Peakman M (2016). T cells in type 1 diabetes: Instructors, regulators and effectors: a comprehensive review. JOURNAL OF AUTOIMMUNITY, 66, 7-16. Author URL.

2015

Knight RR, Dolton G, Kronenberg-Versteeg D, Eichmann M, Zhao M, Huang GC, Beck K, Cole DK, Sewell AK, Skowera A, et al (2015). A distinct immunogenic region of glutamic acid decarboxylase 65 is naturally processed and presented by human islet cells to cytotoxic CD8 T cells. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 179(1), 100-107. Author URL.
Collison JL, Carlin LM, Eichmann M, Geissmann F, Peakman M (2015). Heterogeneity in the Locomotory Behavior of Human Monocyte Subsets over Human Vascular Endothelium in Vitro. JOURNAL OF IMMUNOLOGY, 195(3), 1162-1170. Author URL.
Skowera A, Ladell K, McLaren JE, Dolton G, Matthews KK, Gostick E, Kronenberg-Versteeg D, Eichmann M, Knight RR, Heck S, et al (2015). beta-Cell-Specific CD8 T Cell Phenotype in Type 1 Diabetes Reflects Chronic Autoantigen Exposure. DIABETES, 64(3), 916-925. Author URL.

2014

Eichmann M, de Ru A, van Veelen PA, Peakman M, Kronenberg-Versteeg D (2014). Identification and characterisation of peptide binding motifs of six autoimmune disease-associated human leukocyte antigen-class I molecules including HLA-B*39:06. TISSUE ANTIGENS, 84(4), 378-388. Author URL.

2013

Knight RR, Kronenberg D, Zhao M, Huang GC, Eichmann M, Bulek A, Wooldridge L, Cole DK, Sewell AK, Peakman M, et al (2013). Human beta-Cell Killing by Autoreactive Preproinsulin-Specific CD8 T Cells is Predominantly Granule-Mediated with the Potency Dependent Upon T-Cell Receptor Avidity. DIABETES, 62(1), 205-213. Author URL.
Eichmann M, Peakman M (2013). The role of T lymphocytes in the pathogenesis of autoimmune type 1 diabetes: Implications for potential virus-mediated pathways. In  (Ed) Diabetes and Viruses, 271-286.  Abstract.

2012

Kronenberg D, Knight RR, Estorninho M, Ellis RJ, Kester MG, de Ru A, Eichmann M, Huang GC, Powrie J, Dayan CM, et al (2012). Circulating Preproinsulin Signal Peptide-Specific CD8 T Cells Restricted by the Susceptibility Molecule HLA-A24 Are Expanded at Onset of Type 1 Diabetes and Kill beta-Cells. DIABETES, 61(7), 1752-1759. Author URL.

2011

Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Hoefler H, Hegewisch-Becker S, Folprecht G, et al (2011). Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC CANCER, 11 Author URL.

Martin_Eichmann Details from cache as at 2020-08-04 01:32:24

Refresh publications

Teaching

Supervision / Group

Back | Edit Profile